The commercially available STAT3 inhibitor 5,15-diphenylporphyrin (5,15-DPP) does not directly interact with STAT3 core residues 127–722

[1]  D. Backos,et al.  Strategies and Approaches of Targeting STAT3 for Cancer Treatment. , 2016, ACS chemical biology.

[2]  Guocheng Yuan,et al.  Impact of the N-Terminal Domain of STAT3 in STAT3-Dependent Transcriptional Activity , 2015, Molecular and Cellular Biology.

[3]  F. Baran-Marszak,et al.  STAT3 inhibitors for cancer therapy , 2013, JAK-STAT.

[4]  G. Blatch,et al.  STAT3 interacts directly with Hsp90 , 2012, IUBMB life.

[5]  Adam B Castoreno,et al.  Small molecule probes of cellular pathways and networks. , 2011, ACS chemical biology.

[6]  K. Matsuno,et al.  Novel high-throughput screening system for identifying STAT3-SH2 antagonists. , 2009, Biochemical and biophysical research communications.

[7]  P. Yue,et al.  Targeting STAT3 in cancer: how successful are we? , 2009, Expert opinion on investigational drugs.

[8]  W. Guida,et al.  Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity , 2007, Proceedings of the National Academy of Sciences.

[9]  R. Aebersold,et al.  Expression of a tyrosine phosphorylated, DNA binding Stat3β dimer in bacteria , 1998, FEBS letters.

[10]  S. Becker,et al.  Three-dimensional structure of the Stat3β homodimer bound to DNA , 1998, Nature.

[11]  R. Simpson,et al.  STAT3 forms stable homodimers in the presence of divalent cations prior to activation. , 1998, Biochemical and biophysical research communications.

[12]  F. Baran-Marszak,et al.  STAT 3 inhibitors for cancer therapy Have all roads been explored ? , 2012 .

[13]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..